Profusa, Inc. (PFSA): Nasdaq/NYSE listing notice — NorthView Acquisition Corp. receives Nasdaq notice for MVPHS below $15M; 180-day cure period

Profusa, Inc.

On March 7, 2024, Nasdaq notified NorthView that its MVPHS was below $15 million for 30 consecutive business days.
Company has until September 3, 2024 to regain compliance; stock continues trading on Nasdaq Global Market.
Compliance can be regained if MVPHS closes at $15M+ for ten consecutive business days before deadline.
Previously received notice on Jan 11, 2024 for failing to hold annual meeting; compliance plan submitted and meeting set for March 21, 2024.
Company will evaluate options but cannot assure compliance; potential delisting if not cured by Sept 3, 2024.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Profusa, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5620(a)

Exact text from the filing

January 11, 2024, indicating that the Company had not complied with all of the requirements of the Nasdaq Listing Rule 5620(a) since it has not held an annual meeting of stockholders within 12 months after its fiscal year. Pursuant to the January 11, 2024 letter, the Company submitted its plan of compliance to Nasdaq on February 23, 2024, and subsequently filed a preliminary proxy statement on February 28, 2024, with regard to its annual meeting set to be held on March 21, 2024. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K (the “Current Report”) contains

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Profusa, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-021100

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.